Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × ceralasertib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Ovarian Neoplasms 2 Neoplasms 2 Lung Neoplasms 2 Advanced Solid Tumours 2 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Neoplasms by Site 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Diseases 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hereditary Sensory and Autonomic Neuropathies 1 Endometrial Neoplasms 1 Carcinoma, Bronchogenic 1 Bronchial Neoplasms 1 Advanced Solid Malignancies 1

Interventions

pembrolizumab 146 Nivolumab 98 Ipilimumab 82 Dacarbazine 40 trametinib 34 dabrafenib 30 Vemurafenib 28 atezolizumab 21 binimetinib 19 Temozolomide 19 cemiplimab 16 Paclitaxel 15 cobimetinib 14 spartalizumab 13 encorafenib 12 Cisplatin 12 Carboplatin 12 Cyclophosphamide 10 talimogene laherparepvec 9 lenvatinib 9 durvalumab 9 Docetaxel 9 tremelimumab 8 relatlimab 8 Gemcitabine 8 Drug Therapy 8 Bevacizumab 8 Pemetrexed 7 Albumin-Bound Paclitaxel 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡